PHR — Pharmena SA Income Statement
0.000.00%
- PLN37.87m
- PLN28.01m
- PLN0.27m
- 39
- 28
- 11
- 13
Annual income statement for Pharmena SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | R2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | PAS | PAS | PAS | PAS | PAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9.93 | 15.2 | 0.299 | 1.25 | 0.268 |
Cost of Revenue | |||||
Gross Profit | 5.08 | 7.83 | 0.091 | 0.868 | 0.198 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 15.9 | 19.2 | 4.35 | -32.7 | 3.67 |
Operating Profit | -6.01 | -3.98 | -4.05 | 33.9 | -3.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.27 | -4.46 | -4.95 | -12 | -2.56 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.96 | -4.64 | -5.16 | -17.8 | -1.26 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -6.89 | -4.59 | -1.57 | -15.9 | -1.26 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.89 | -4.59 | -1.57 | -15.9 | -1.26 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.624 | -0.403 | -0.454 | -3.75 | -0.112 |
Dividends per Share |